OVER DEZE AFLEVERING

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Wetenschap

Geneeskunde

Engels

Verenigde Staten

GebruikAPIom deze aflevering op te halen inJSON

LAAT NOTITIES ZIEN 🔗

00:00:00Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL)

00:04:10Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring

00:10:05Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL

00:15:22Pirtobrutinib as first-line therapy for CLL and long-term safety data

TRANSCRIPTIE 🔗

Are you the producer of this podcast? Add a podcast transcript

Need Audio-to-Text? Transcribe with Listen411 in Just 60 Seconds

OUDE AFLEVERINGEN ZOEKEN

Zoek naar eerdere afleveringen van Hematologic Oncology Update.

Sluit deze zoekbalk in op uw website

ANDERE AFLEVERINGEN IN DEZE PODCAST

$Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting$

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting

12 oktober 2026

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: Introduction (0:00) New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20) Utility …

00:59:31

OPSLAAN

Clip

Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

1 oktober 2026

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications

00:50:22

OPSLAAN

Clip

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management

8 oktober 2026

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: Introduction (0:00) Minimal Residual Disease Assays in Community-Based Practice (1:24) New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12) Richter T…

00:58:15

OPSLAAN

Clip

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

5 oktober 2026

Featuring an interview with Dr L Elizabeth Budde, including the following topics: Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) Management of BsAb-induced cytokine release syndrome and other toxicities (7:35) Use of BsAbs in the f…

00:47:06

OPSLAAN

Clip

Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van Dr. Neil Love, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.